UroGen Pharma Ltd. (URGN) Formed Double Top Chart Pattern; Buyers Could Thrive

June 20, 2018 - By Peter Erickson

The chart of UroGen Pharma Ltd. (URGN) shows a double top with $57.06 target or 3.00 % above today’s $55.40 share price. The 5 months chart pattern indicates low risk for the $857.26M company. It was reported on Jun, 20 by Finviz.com. If the $57.06 price target is reached, the company will be worth $25.72 million more. Double tops are rare but powerful chart patterns.

The stock decreased 0.54% or $0.3 during the last trading session, reaching $55.4. About 74,839 shares traded. UroGen Pharma Ltd. (NASDAQ:URGN) has risen 228.14% since June 20, 2017 and is uptrending. It has outperformed by 215.57% the S&P500.

Analysts await UroGen Pharma Ltd. (NASDAQ:URGN) to report earnings on August, 13. They expect $-0.91 EPS, down 30.00 % or $0.21 from last year’s $-0.7 per share. After $-0.88 actual EPS reported by UroGen Pharma Ltd. for the previous quarter, Wall Street now forecasts 3.41 % negative EPS growth.

More important recent UroGen Pharma Ltd. (NASDAQ:URGN) news were published by: Globenewswire.com which released: “Investor Expectations to Drive Momentum within Mesoblast, Access National, Urogen Pharma, TechTarget, Sina, and …” on June 06, 2018, also Streetinsider.com published article titled: “UroGen Pharma (URGN) Names Stephen Mullennix Interim CFO, Replacing Gary Titus”, Nasdaq.com published: “UroGen Pharma’s Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award” on June 13, 2018. More interesting news about UroGen Pharma Ltd. (NASDAQ:URGN) was released by: Nasdaq.com and their article: “UroGen Pharma to Present at the Jefferies 2018 Global Healthcare Conference” with publication date: May 29, 2018.

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company has market cap of $857.26 million. The Company’s lead product candidates, MitoGel and VesiGel are formulations of the chemotherapy drug Mitomycin C, a generic drug which is currently used off-label for urothelial cancer treatment only in a water formulation as an adjuvant, or supplemental post-surgery, therapy. It currently has negative earnings. The firm is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer.

UroGen Pharma Ltd. (NASDAQ:URGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: